On November 3, 2022 Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, reported that five abstracts will be presented from the KER-050 and KER-047 hematology programs at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) ("ASH") Annual Meeting and Exposition, to be held in person and virtually from December 10 through 13, 2022 (Press release, Keros Therapeutics, NOV 3, 2022, View Source [SID1234622923]). Keros will be presenting additional and initial preliminary results, respectively, from its two Phase 2 clinical trials of KER-050, one in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes ("MDS") and one in patients with myelofibrosis. In addition, Keros will be presenting preliminary results from its Phase 2 clinical trial of KER-047 in patients with iron-refractory iron deficiency anemia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to have multiple abstracts accepted for presentation at ASH (Free ASH Whitepaper), which provides us with the opportunity to share updates from our preclinical and Phase 2 clinical programs, including biomarker data from our ongoing Phase 2 clinical trial of KER-050 in patients with MDS," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. "We remain on track to release additional efficacy data from our KER-050 Phase 2 MDS trial by mid-December 2022."

The following abstracts were posted to the ASH (Free ASH Whitepaper) website on November 3, 2022, 9:00 a.m. Eastern time.

Clinical Presentations

"Preliminary Results of a Phase-2 Clinical Trial of the ALK-2 Inhibitor KER-047 for Treatment of Iron-Refractory Iron Deficiency Anemia"

•Publication Number: 1028
•Session Name: 102. Iron Homeostasis and Biology: Poster I
•Date: Saturday, December 10, 2022
•Presentation Time: 5:30 p.m. – 7:30 p.m. Central time

"Effects of KER-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes"

•Publication Number: 3656
•Session Name: 102. Iron Homeostasis and Biology: Poster III
•Date: Monday, December 12, 2022
•Presentation Time: 6:00 p.m. – 8:00 p.m. Central time

"Modulation of TGF-β Superfamily Signaling to Treat Myelofibrosis and Mitigate JAK Inhibitor Toxicity: A Report on the Phase 2 Study of KER-050 in Participants with Myelofibrosis"

•Publication Number: 4361
•Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
•Date: Monday, December 12, 2022
•Presentation Time: 6:00 p.m. – 8:00 p.m. Central time

Preclinical Presentations

"ALK2 Inhibition and a Modified Activin Receptor Type IIA Ligand Trap Cotherapy Maximized Hematologic Improvements in a Mouse Model of Anemia of Inflammation"

•Publication Number: 2338
•Session Name: 102. Iron Homeostasis and Biology: Poster II
•Date: Sunday, December 11, 2022
•Presentation Time: 6:00 p.m. – 8:00 p.m. Central time

"RKER-050, a Novel Activin Receptor Type II Ligand Trap, Rescued Anemia and Reduced Bone Loss in a Mouse Model of Myelodysplastic Syndromes"

•Publication Number: 4387
•Session Name: 636. Myelodysplastic Syndromes – Basic and Translational: Poster III
•Date: Monday, December 12, 2022
•Presentation Time: 6:00 p.m. – 8:00 p.m. Central time

About KER-050

Keros’ lead protein therapeutic product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the transforming growth factor-beta ("TGF-β") superfamily receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with MDS and in patients with myelofibrosis.

About KER-047

Keros’ lead small molecule product candidate, KER-047, is designed to selectively and potently inhibit activin receptor-like kinase-2, a TGF-β superfamily receptor. KER-047 is being developed for the treatment of functional iron deficiency which is a consequence of elevated ALK2 signaling.